The estrogen receptor-α agonist 16α-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats

Cardiovascular Research

Volumn 67, Issue 4, 2005, Pages 604-612

  Pelzer, Theo ^a   Jazbutyte, Virginija ^a   Hu, Kai ^a   Segerer, Stephan ^a   Nahrendorf, Matthias ^a   Nordbeck, Peter ^a   Bonz, Andreas W ^a   Muck, Jenny ^a   Fritzemeier, Karl Heinrich ^b   Hegele Hartung, Christa ^b   Ertl, Georg ^a   Neyses, Ludwig ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac hypertrophy; Estrogen receptor; Spontaneously hypertensive rats

Indexed keywords

ESTRADIOL; ESTRADIOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; HEART MUSCLE CELL; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; HEMODYNAMIC PROCESSES; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MODELS, ANIMAL; MYOCARDIUM; MYOSIN HEAVY CHAINS; ORGAN SIZE; OVARIECTOMY; PAPILLARY MUSCLES; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; TAMOXIFEN; VENTRICULAR MYOSINS;

EID: 22744459921     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.04.035     Document Type: Article

References (29)

1. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
2. J.D. Carroll, E.P. Carroll, T. Feldman, D.M. Ward, R.M. Lang, and D. McGaughey Sex-associated differences in left ventricular function in aortic stenosis of the elderly Circulation 86 1992 1099 1197
3. H.M. Krumholz, M. Larson, and D. Levy Sex differences in cardiac adaptation to isolated systolic hypertension Am J Cardiol 72 1993 310 313
4. M. van Eickels, C. Grohe, J.P. Cleutjens, B.J. Janssen, H.J. Wellens, and P.A. Doevendans 17beta-estradiol attenuates the development of pressure-overload hypertrophy Circulation 104 2001 1419 1423
5. T. Pelzer, T. de Jager, J. Muck, M. Stimpel, and L. Neyses Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition J Hypertens 20 2002 1001 1006
6. C.S. Hayward, C.M. Webb, and P. Collins Effect of sex hormones on cardiac mass Lancet 357 2001 1354 1356
7. J.M. Hall, J.F. Couse, and K.S. Korach The multifaceted mechanisms of estradiol and estrogen receptor signaling J Biol Chem 276 2001 36869 36872
8. A. Hillisch, O. Peters, D. Kosemund, G. Muller, A. Walter, and B. Schneider Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design Mol Endocrinol 18 2004 1599 1609
9. J. Widder, T. Pelzer, C. von Poser-Klein, K. Hu, V. Jazbutyte, and K.H. Fritzemeier Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR Hypertension 42 2003 991 996
10. C. Hegele-Hartung, P. Siebel, O. Peters, D. Kosemund, G. Muller, and A. Hillisch Impact of isotype-selective estrogen receptor agonists on ovarian function Proc Natl Acad Sci U S A 101 2004 5129 5134
11. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
12. D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, and M. Hlatky Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II) JAMA 288 2002 49 57
13. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
14. N.K. Wenger, E. Barrett-Connor, P. Collins, D. Grady, M. Kornitzer, and L. Mosca Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial Am J Cardiol 90 2002 1204 1210
15. D.M. Herrington, B.E. Pusser, W.A. Riley, T.Y. Thuren, K.B. Brosnihan, and E.A. Brinton Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women Arterioscler Thromb Vasc Biol 20 2000 1606 1612
16. D. Fraccarollo, K. Hu, P. Galuppo, P. Gaudron, and G. Ertl Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling Circulation 96 1997 3963 3973
17. M. Nahrendorf, F. Wiesmann, K.H. Hiller, H. Han, K. Hu, and C. Waller In vivo assessment of cardiac remodeling after myocardial infarction in rats by cine-magnetic resonance imaging J Cardiovasc Magn Reson 2 2000 171 180
18. A.W. Bonz, S. Kniesch, U. Hofmann, S. Kullmer, L. Bauer, and H. Wagner Functional properties and [Ca(2+)](i) metabolism of creatine kinase-KO mice myocardium Biochem Biophys Res Commun 298 2002 163 168
19. F.A. Babiker, L.J. De Windt, M. van Eickels, V. Thijssen, R.J. Bronsaer, and C. Grohe 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway Circulation 109 2004 269 276
20. A.E. Wakeling, M. Dukes, and J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res 51 1991 3867 3873
21. J.D. Molkentin Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs Cardiovasc Res 63 2004 467 475
22. H. Ogita, K. Node, Y. Liao, F. Ishikura, S. Beppu, and H. Asanuma Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice Hypertension 43 2004 237 242
23. P. Liao, D. Georgakopoulos, A. Kovacs, M. Zheng, D. Lerner, and H. Pu The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy Proc Natl Acad Sci U S A 98 2001 12283 12288
24. J.C. Braz, O.F. Bueno, Q. Liang, B.J. Wilkins, Y.S. Dai, and S. Parsons Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling J Clin Invest 111 2003 1475 1486
25. B. Fiedler, and KC. Wollert Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes Cardiovasc Res 63 2004 450 457
26. M.E. Beyer, G. Yu, H. Hanke, and H.M. Hoffmeister Acute gender-specific hemodynamic and inotropic effects of 17beta-estradiol on rats Hypertension 38 2001 1003 1010
27. A.M. Lompre, K. Schwartz, A. d'Albis, G. Lacombe, N. Van Thiem, and B. Swynghedauw Myosin isoenzyme redistribution in chronic heart overload Nature 282 1979 105 107
28. W. Schillinger, J.W. Fiolet, K. Schlotthauer, and G. Hasenfuss Relevance of Na+-Ca2+exchange in heart failure Cardiovasc Res 57 2003 921 933
29. J.C. Tardiff, T.E. Hewett, S.M. Factor, K.L. Vikstrom, J. Robbins, and L.A. Leinwand Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects Am J Physiol Heart Circ Physiol 278 2000 H412 H419